While RAS is predominantly in its GDP-bound inactive state in normal quiescent cells, mutations in KRAS render it persistently GTP-bound and constitutively active, independent of extracellular stimuli, resulting in the activation of effector signaling pathways that drive cancer growth [3,4]. The gene discussed is KRAS; the disease is cancer.